HM6: Real-world evidence and the use of big data for regulatory decision making; DARWIN EU

HM6

The session brought together perspectives, from both regulators and the pharmaceutical industry, on the potential that real-world evidence (RWE) can bring to the acknowledgement of the value of medicines post-marketing authorisation.

It is well recognised that as science advances and brings new treatments online, regulatory science must also evolve to make proper and rigorous assessments. Defining what is the right data to be generated, and enabling its use, by recognising its value is increasingly affecting the regulatory science agenda across the world. Eventually, such data can be used to support regulatory applications, leading to better decisions that could allow enhanced access from patients.

 This is member-only content

To read this article, SIGN IN NOW if you are a TOPRA member.

 

Not a TOPRA member yet? Join our global community.

Five great reasons to become a TOPRA member:

  1. Great savings on our events and training.
  2. Be part of our dynamic international community.
  3. Contribute to the profession.
  4. Grow your skills and knowledge.
  5. Take your career to the next level.

Have you heard what you’re missing? Listen now to the RegRapPod podcast show, for free!